1. Generics Bulletin
  2. >>Business

Lupin Seeks Partners For Biosimilars And Oncology Research

FY22 Guidance Lowered

 
• By Vibha Ravi

Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.

Handshake signifying partnership
Will Lupin Get The Partner It Is Looking For? • Source: Alamy

Lupin Limited is considering partnerships for its research on biosimilars, specialty generics and new chemical entities (NCEs), with several oncology assets recently spun off under wholly owned US subsidiary Lupin Oncology Inc. being first in line for a tie-up.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Generics Bulletin